Login
$LSTA
$1.10 +$0.01 (0.92%) After hours

$LSTA 8-K/A SEC Filings

Filed On Filing
12 Nov 2026 8-K/A: Financial Statements and Exhibits

We have audited the combined financial statements of Marea Therapeutics, Inc. and M2 Therapeutics, Inc. (together, “the Company”), which comprise the combined balance sheets as of December 31, 2025 and 2024, and the related combined stat...

14 Oct 2022 8-K/A: Financial Statements and Exhibits

We consent to the incorporation by reference of our report dated May 20, 2022, relating to the consolidated financial statements of Cend Therapeutics, Inc. appearing in Registration Statement No. 333-265638 on Form S-4, Amendment No. 1, ...

04 Oct 2022 8-K/A: Other Events

On April 26, 2022, Caladrius Biosciences, Inc. (“Caladrius”), CS Cedar Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Caladrius (“Merger Sub”), and Cend Therapeutics, Inc. (“Cend” or the “Company”), a privately-h...

11 Apr 2019 8-K/A: Regulation FD Disclosure

Corporate Presentation David J. Mazzo, PhD President and Chief Executive Officer April 2019 | NASDAQ: CLBS

14 Mar 2016 8-K/A: Costs Associated with Exit or Disposal Activities; Material Impairments

On January 6, 2016, the Company’s Board made the Phase III Study Termination decision. The Board made this determination based on the accelerating adoption of alternative treatments as described in the Press Release, as described in Item...

30 Jun 2011 8-K/A: Changes in Registrant's Certifying Accountant

We have read Item 4.01 of NeoStem, Inc.’s Form 8-K/A dated June 23, 2011, and we agree with the statements made therein.

14 Jun 2011 8-K/A: Regulation FD Disclosure

Attached as Exhibit 99.2 is a revised slide presentation. It is being furnished to correct a typographical error on slide 21 of the slide presentation attached to NeoStem’s Current Report on Form 8-K dated June 13, 2011.

06 Apr 2010 8-K/A: Changes in Registrant's Certifying Accountant

As previously disclosed in the Form 8-K, on March 11, 2010, the Audit Committee of the Board of Directors of the Company, determined that Holtz Rubenstein Reminick would not be appointed as the Company's independent registered public acc...

05 Jan 2010 8-K/A: Financial Statements and Exhibits

The financial statements required by Rule 8-04(b) of Regulation S-X (consisting of (i) the audited consolidated balance sheets of China Biopharmaceuticals Holdings, Inc. (“CBH”) and subsidiaries as of December 31, 2008 and 2007; the rela...

09 Sep 2009 8-K/A: Entry into a Material Definitive Agreement

NeoStem has entered into an agreement for the lease of space from Rivertech Associates II, LLC, c/o The Abbey Group (the “Landlord”) at 840 Memorial Drive, Cambridge, Massachusetts with a lease term effective September 1, 2009 through Au...

13 Feb 2003 8-K/A: Other Events

1. Purpose of the Plan. The Corniche Group Incorporated 2003 Equity Participation Plan (the "Plan") is intended to advance the interests of Corniche Group Incorporated (the "Company") by inducing individuals or entities of outstanding ab...

08 Mar 1996 8-K/A: Financial Statements and Exhibits

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support